A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM

Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized! Mainstay remains weight loss and exercise! @RheumNow #ACR23 Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4

McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT

Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu

The DICKENS study showed no significant improvement in knee pain(p=0.77), WOMAC pain(p=0.64) or function(p=0.68) & stiffness(p=0.34) between diacerin and pbo over 24wks. ⬆️AEs in diacerin grp-diarrhea, colored urine #ACR23 ABSTL05 @RheumNow https://t.co/ht0pGN38il

Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0

A#2427 #ACR23 @RheumNow PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium Density of PR3+ higher in glomueruli of prolif LN Correlates with activity, not chronicity Urinary PR3 predict renal fxn loss at 3y @jhrheumatology @andreafava https://t.co/vvC8lgZgWO

APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz

What drives fate of synovial fibroblast into being a lining fibroblast? Presti et al., organoid culture approach: -Beta catenin seems instrumental -Cadherin 23 is specific & drives compaction Big implications for elective FLS targeted ttmt! @RheumNow #ACR23 ABST2426 https://t.co/9R5AhwE9rQ

Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X

Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9

@rheumnow and Dr Kevin Winthrop #ACR23 - watch what they to say about #COVID #vaccines on https://t.co/2zKD625Yn9 https://t.co/9tCOgNLyO7

• An Interview with Kevin Winthrop: Three Questions About COVID 19 | RheumNow

MANDARA -52wk,ph3 non-inferiority study comparing efficacy & safety of benralizumab & mepolizumab in EGPA receiving SOC 👉Benralizumab was non-inferior to mepolizumab in achieving remission at wks 36 & 48 (2.71%; 95% CI –12.54, 17.96; p=0.7278) #ACR ABSTL14 @RheumNow #ACRbest https://t.co/S3aa3g5mnN

K-drama! Korean database noted smokers and ex-smokers had less OA fewer TKR! These were age, comorbidities matched. Unclear what the data is for sex difference or occupation. Other pubs in the past noted similar observations. Abst#1808 @rheumnow #ACR23 @UnaMakris https://t.co/ZkjWoxD8wD

#ACR23 Abstr#2270 What are the causes of discordance btw #SLE patients and physicians pertaining to disease activity? Survey data from Global COVAD: 45% rate of discordance! Could be related to fatigue levels, pain, poor mental being & impaired physical function @RheumNow https://t.co/kVzGRJm2R8